Femasys is a biomedical company focused on transforming women's healthcare by developing solutions to address severely underserved areas. Co. operates as one segment and is focused on servicing the reproductive health needs for those seeking permanent birth control or solutions for infertility issues. FemBloc® (FemBloc), Co.'s solution for permanent birth control, is based on Co.'s non-surgical platform technology. FemChec® Pressure Management Device evaluates the women's fallopian tubes after a FemBloc procedure and is part of the FemBloc validation study. FemCerv® Endocervical Sampler is designed to collect a complete, non-contaminated cervical tissue sample. The FEMY average annual return since 2021 is shown above.
The Average Annual Return on the FEMY average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether FEMY average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FEMY average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|